Deploying Disruptive Technologies to Streamline End-to-End Process Development & Manufacture Effective, Safe & Consistent Cell Therapies In-Line with Quality by Design Principles
June 11-13, 2024 | Boston, MA
In today's ever-evolving cell therapy landscape, cost-efficient process innovation is essential for maximizing funding and gaining a competitive edge in the market. The 3rd Process Development for Cell Therapies Summit is your premier platform for enhancing process efficiency, scalability, and speed while keeping costs in check!
Join industry leaders from renowned organizations like BMS, Beam Therapeutics, 2seventy Bio, Takeda, Century Therapeutics, AstraZeneca, and more to accelerate your journey from IND to BLA submission. Benefit from insights on enforcing an effective control strategy, optimizing starting material quality, introducing post-IND process enhancements, integrating automation and much more!
Don't miss this opportunity to collaborate, share insights, and shape the future of cell therapy together. Together, let's drive the development of consistent, scalable, and cost-effective autologous and allogeneic cell therapies!
“The organizers were phenomenal, very helpful and resourceful. The entire conference was amazing and the interactions that resulted was outstanding.”
– Cell & Gene Therapy Specialist, VOR Biopharma
“The ability to talk to leaders in the industry was awesome. Great time for networking and learning new ways of approaching some of our current problems in the industry.”
- Process Development Engineer, Inceptor Bio
“It was hyper specific to our industry which is hard to find at other conferences. Super helpful and the hosts were amazing.”
- Senior Associate Scientist, Bluebird Bio
“Being around other professionals in the process development space was exciting and informative. Realizing we are all dealing with similar issues was helpful and I would love to attend next year and see what progress people have made.”
- Senior Associate Scientist, Process Development, Sonoma Biotherapeutics
